默沙东，中国区大幅下跌62%的背后是什么？

药闻康策2025-05-08

2025年，默沙东（MSD）发布的财报显示，其中国区销售额同比骤降62%，创下近十年最大跌幅。这一数据不仅暴露了这家跨国药企在中国市场的深层危机，更折射出中国医疗健康产业格局的剧烈重构。本文将结合2025年行业动态，剖析暴跌背后的核心动因，并探讨其对资本市场的影响。数据背后的“三重绞杀”集采冲击：价格坍塌与利润压缩2025年，中国带量采购已覆盖肿瘤药、慢病药等核心领域，默沙东的拳头产品...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2533294323?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-08 00:01","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2533294323","market":"us","top_or_hot":-1,"title":"默沙东，中国区大幅下跌62%的背后是什么？","media":"药闻康策","content":"<div>\n<p>2025年，默沙东（MSD）发布的财报显示，其中国区销售额同比骤降62%，创下近十年最大跌幅。这一数据不仅暴露了这家跨国药企在中国市场的深层危机，更折射出中国医疗健康产业格局的剧烈重构。本文将结合2025年行业动态，剖析暴跌背后的核心动因，并探讨其对资本市场的影响。数据背后的“三重绞杀”集采冲击：价格坍塌与利润压缩2025年，中国带量采购已覆盖肿瘤药、慢病药等核心领域，默沙东的拳头产品...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508043244a6d6bf7a&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>默沙东，中国区大幅下跌62%的背后是什么？</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n默沙东，中国区大幅下跌62%的背后是什么？\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-08 00:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508043244a6d6bf7a&s=b><strong>药闻康策</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2025年，默沙东（MSD）发布的财报显示，其中国区销售额同比骤降62%，创下近十年最大跌幅。这一数据不仅暴露了这家跨国药企在中国市场的深层危机，更折射出中国医疗健康产业格局的剧烈重构。本文将结合2025年行业动态，剖析暴跌背后的核心动因，并探讨其对资本市场的影响。数据背后的“三重绞杀”集采冲击：价格坍塌与利润压缩2025年，中国带量采购已覆盖肿瘤药、慢病药等核心领域，默沙东的拳头产品...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508043244a6d6bf7a&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BJJMRZ35.SGD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508043244a6d6bf7a&s=b","article_id":"2533294323","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250508043244a6d6bf7a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2533294323","pubTimestamp":1746633715,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"2025年，默沙东发布的财报显示，其中国区销售额同比骤降62%，创下近十年最大跌幅。此外，信达生物的PD-1/VEGF双抗药物凭借适应症拓展，直接冲击默沙东的联合用药市场。产品管线依赖与创新断层默沙东中国区收入仍依赖Keytruda等成熟产品，占其总营收的60%，而2025年其管线中仅有一款针对肝癌的TIGIT抑制剂获批，远落后于国内药企在ADC、双抗等领域的密集突破。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4550":"红杉资本持仓","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0861579265.USD":"联博低波幅策略股票基金A","LU0122379950.USD":"贝莱德世界健康科学A2","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","BK4007":"制药","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","SG9999014559.SGD":"United Income Focus Trust Dis SGD","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","MRK":"默沙东","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU1069347547.HKD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (HKD) INC","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","SG9999002232.USD":"Allianz Global High Payout USD","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC"},"translate_title":"Merck, what is behind the sharp drop of 62% in China?","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRK":1},"content_text":"2025年，默沙东（MSD）发布的财报显示，其中国区销售额同比骤降62%，创下近十年最大跌幅。这一数据不仅暴露了这家跨国药企在中国市场的深层危机，更折射出中国医疗健康产业格局的剧烈重构。本文将结合2025年行业动态，剖析暴跌背后的核心动因，并探讨其对资本市场的影响。数据背后的“三重绞杀”集采冲击：价格坍塌与利润压缩2025年，中国带量采购已覆盖肿瘤药、慢病药等核心领域，默沙东的拳头产品Keytruda（PD-1抑制剂）被纳入第八批集采，单支价格从约3000元降至500元以下，降幅超80%。尽管销量增长35%，但收入贡献同比萎缩68%。同时，其HPV疫苗等重磅产品因国产竞品上市，市场份额从45%下滑至18%。国产创新药“围剿”加速恒瑞医药、百济神州等企业的PD-1药物在2025年实现销售额合计超200亿元，凭借价格仅为进口药1/3的优势，占据70%的国内市场。此外，信达生物的PD-1/VEGF双抗药物凭借适应症拓展，直接冲击默沙东的联合用药市场。产品管线依赖与创新断层默沙东中国区收入仍依赖Keytruda等成熟产品，占其总营收的60%，而2025年其管线中仅有一款针对肝癌的TIGIT抑制剂获批，远落后于国内药企在ADC（抗体偶联药物）、双抗等领域的密集突破。行业变局：本土化与创新转型的生死赛跑跨国药企的“本土化突围”默沙东尝试与药明康德合作开发针对亚洲高发癌症的改良型药物，但本土化生产与审批速度仍落后于恒瑞等企业。相比之下，辉瑞通过将研发中心落地苏州，其CDK4/6抑制剂上市时间缩短6个月，抢占先机。政策导向下的市场再分配中国医保局2025年推出“创新药优先谈判”机制，国产PD-1药物平均进入医保时间缩短至10个月，而进口药需额外提供真实世界数据，进一步削弱其竞争力。同时，“应采尽采”范围扩展至中药创新药，倒逼跨国药企调整产品策略。资本流向：从“跟随创新”到“原创博弈”2025年，港交所科创板生物医药板块募资额同比增40%，康方生物、科伦药业等企业的双抗和ADC管线获得百亿级融资。资本对“me-too”药物的投资锐减70%，转向更具全球竞争力的技术平台。未来展望：存量博弈下的生存法则默沙东已启动“中国2030战略”，包括裁员30%的销售团队、将60%研发预算投向细胞疗法，并寻求与阿里健康合作拓展数字化营销。然而，其能否扭转颓势，取决于能否在2028年Keytruda专利到期前，推出可替代的重磅产品。对资本市场而言，这一暴跌标志着中国医药市场进入“质变期”：跨国药企的“超国民待遇”终结，国产创新药从“仿制跟随”迈向“原始创新”。未来，拥有强研发管线的本土企业（如百济神州、信达生物）和深度本土化的跨国公司（如诺和诺德中国研发中心）或将成为赢家。(来源：医药智投）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2533294323","isCrawlerRequest":true}